|94.22||-0.8700||-0.91%||Vol 740.17K||1Y Perf 37.18%|
|Feb 3rd, 2023 16:00 DELAYED|
|- -||-0.12 -0.13%|
|Target Price||107.43||Analyst Rating||Hold 2.75|
|Potential %||14.02||Finscreener Ranking||★ 40.80|
|Insiders Trans % 3/6/12 mo.||-100/-100/-89||Value Ranking||★ 39.72|
|Insiders Value % 3/6/12 mo.||-100/-100/-89||Growth Ranking||★★ 45.24|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-89||Income Ranking||— -|
|Price Range Ratio 52W %||59.44||Earnings Rating||Strong Buy|
|Market Cap||9.89B||Earnings Date||23rd Feb 2023|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Buy|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||23rd Feb 2023|
|Estimated EPS Next Report||-0.32|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||865.01K|
|Avg. Monthly Volume||1.69M|
|Avg. Quarterly Volume||931.44K|
NovoCure Limited (NASDAQ: NVCR) stock closed at 94.22 per share at the end of the most recent trading day (a -0.91% change compared to the prior day closing price) with a volume of 740.17K shares and market capitalization of 9.89B. Is a component of Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 1023 people. NovoCure Limited CEO is Asaf Danziger.
The one-year performance of NovoCure Limited stock is 37.18%, while year-to-date (YTD) performance is 28.45%. NVCR stock has a five-year performance of 342.35%. Its 52-week range is between 56.39 and 120.03, which gives NVCR stock a 52-week price range ratio of 59.44%
NovoCure Limited currently has a PE ratio of -141.60, a price-to-book (PB) ratio of 25.69, a price-to-sale (PS) ratio of 23.39, a price to cashflow ratio of 232.80, a PEG ratio of 2.32, a ROA of -7.69%, a ROC of -8.12% and a ROE of -20.54%. The company’s profit margin is -13.49%, its EBITDA margin is -11.70%, and its revenue ttm is $409.41 Million , which makes it $3.90 revenue per share.
Of the last four earnings reports from NovoCure Limited, there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.32 for the next earnings report. NovoCure Limited’s next earnings report date is 23rd Feb 2023.
The consensus rating of Wall Street analysts for NovoCure Limited is Hold (2.75), with a target price of $107.43, which is +14.02% compared to the current price. The earnings rating for NovoCure Limited stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
NovoCure Limited has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
NovoCure Limited has a Buy technical analysis rating based on Technical Indicators (ADX : 19.16, ATR14 : 5.36, CCI20 : 23.39, Chaikin Money Flow : -0.09, MACD : 2.70, Money Flow Index : 46.78, ROC : 1.50, RSI : 57.75, STOCH (14,3) : 84.56, STOCH RSI : 0.76, UO : 58.87, Williams %R : -15.44), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of NovoCure Limited in the last 12-months were: Asaf Danziger (Sold 0 shares of value $-1 627 125 ), Asaf Danziger (Sold 212 500 shares of value $23 106 230 ), Ashley Cordova (Sold 0 shares of value $0 ), Ashley Cordova (Sold 3 349 shares of value $247 898 ), Ely Benaim (Sold 12 914 shares of value $901 551 ), Frank Leonard (Sold 0 shares of value $-468 670 ), Frank Leonard (Sold 138 762 shares of value $12 188 798 ), Jeryl L. Hilleman (Sold 407 shares of value $28 331 ), Pritesh Shah (Sold 13 974 shares of value $1 007 237 ), Todd Christopher Longsworth (Sold 5 406 shares of value $384 378 ), Uri Weinberg (Sold 0 shares of value $-91 540 ), Uri Weinberg (Sold 8 143 shares of value $945 756 ), Wilhelmus C. M. Groenhuysen (Sold 7 089 shares of value $506 095 ), William F. Doyle (Sold 3 222 shares of value $225 493 ), William Patrick Burke (Sold 3 122 shares of value $227 084 )
Thu, 12 Jan 2023 11:15 GMT NovoCure (NVCR) Receives a Buy from H.C. Wainwright- TipRanks. All rights reserved.
Fri, 29 Jul 2022 12:24 GMT NovoCure (NVCR) Receives a Hold from J.P. Morgan- TipRanks. All rights reserved.
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.